← Back to Aurobindo Pharma Ltd. overview
Aurobindo Pharma Ltd. — 10-Year Financials
Annual P&L, balance sheet, and key ratios from public BSE/NSE filings.
| Period | Revenue | Net Profit | EPS (₹) | Total Assets | Shareholder Equity | ROE (%) | ROCE (%) | D/E | Net Margin (%) |
|---|---|---|---|---|---|---|---|---|---|
| FY2025 | ₹31,378 cr | ₹3,486 cr | ₹59.81 | ₹49,785 cr | ₹32,653 cr | 10.68% | 13.46% | 0.25x | 11.11% |
| FY2024 | ₹28,705 cr | ₹3,173 cr | ₹54.16 | ₹45,072 cr | ₹29,843 cr | 10.63% | 12.74% | 0.22x | 11.05% |
| FY2023 | ₹24,617 cr | ₹1,928 cr | ₹32.9 | ₹39,890 cr | ₹26,840 cr | 7.18% | 8.53% | 0.2x | 7.83% |
| FY2022 | ₹23,367 cr | ₹2,648 cr | ₹45.19 | ₹33,922 cr | ₹24,576 cr | 10.78% | 12.24% | 0.13x | 11.33% |
Revenue: Total income from operations (₹ crore).
EPS: Earnings per share (₹), basic.
ROE: Net profit / average shareholder equity.
ROCE: EBIT / capital employed.
D/E: Total debt / shareholder equity.
Net Margin: Net profit as a % of revenue.
All figures sourced from public BSE/NSE filings. Ratios are pre-computed estimates and may differ from primary filings due to rounding.
Educational content — not investment adviceAll financial data is sourced from public filings and shown here for educational purposes only. EquitiesIndia.com is not a SEBI-registered Investment Adviser or Research Analyst. Nothing on this page constitutes a recommendation or solicitation to transact in any security. All data is at least 90 days old. Past performance is not indicative of future results.